Handbook_Volume III

115 Bibliografia [1] Socie C, Stone JV, Wingard JR. Long term survival and late deaths after allogenic bone marrow transplantation. Late Effects Working Commette of the International Bone Marrow Transplant Registry. N Engl J Med. 1999 Jul 1;341 (1):14-2 [2] Wingard JR, Majhail NS, Brazauskas R, et al: Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011 29: 2230-2239 [3] Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Blood Marrow Transplant. 2012; 18: 348-71 [4] DeFilipp Z, Duarte RF, Snowden JA, et al. Complications and Quality of Life Working Party, metabolic syndrome and cardiovascular disease fol- lowing hematopoietic cell transplantation: screen- ing and preventive practice recommendations from CIBMTR and EBMT. BMT. 2017; 52: 173-82 [5] Tichelli A, Bucher C, Rovo A. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007; 110: 3463-71 [6] Majhail NS, Flowers ME, Ness KK, et al. High preva- lence of metabolic syndrome after allogeneic hemato- poietic cell transplantation. Bone Marrow Transplant. 2009b;43:49–54 [7] Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41:797–804 [8] Griffith ML, Jagasia M, Jagasia SM. Diabetes mellitus after 1. Aspetti Generali hematopoietic stem cell transplantation. Endocr Pract. 2010; 16:699–706 [9] Sanders JE, Paul AH, Woolfrey AE, et al. Thyroid func- tion following hematopoietic cell transplantation in children: 30 years’ experience. Blood. 2009;113: 306–8. [10] Socie G, Salooja N, Cohen A. Nonmalignant late effects after allogenic stem cell transplantation. Blood.2003, vol 101 9 pg3373-3385. [11] Dalle JH, Lucchini G, Balduzzi A, et al. State-of-the- art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2017;52:1029–35 [12] Balduzzi A, Dalle JH, Jahnukainen K, et al. Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transplant. 2017;52:1406–15 [13] Syrjala KL, Kurland BF, Abrams JR, et al. Sexual func- tion changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood. 2008;111:989–96 [14] Visani G, Guiducci B, Giardini C, et al. Deferasirox improves hematopoiesis after allogeneic hematopoi- etic SCT. Bone Marrow Transplant. 2014;49:585–7 [15] Rizzo JD, Curtis RE, Socie G. Solid cancer after allogeneic hematopoietic cell transplantation. Blood. 2009; 113:1175-83